Ibafloxacin (INN) is a fluoroquinolone antibiotic[1] drug formally approved for use in the European Union for veterinary medicine.[2]

Ibafloxacin
Clinical data
Trade namesIbaflin
AHFS/Drugs.comInternational Drug Names
ATCvet code
Legal status
Legal status
Identifiers
  • 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H14FNO3
Molar mass275.279 g·mol−1
3D model (JSmol)
  • Fc2cc1C(=O)/C(C(=O)O)=C\N3c1c(c2C)CCC3C
  • InChI=1S/C15H14FNO3/c1-7-3-4-9-8(2)12(16)5-10-13(9)17(7)6-11(14(10)18)15(19)20/h5-7H,3-4H2,1-2H3,(H,19,20) ☒N
  • Key:DXKRGNXUIRKXNR-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Horspool LJ, van Laar P, van den Bos R, Mawhinney I (June 2004). "Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles". Journal of Veterinary Pharmacology and Therapeutics. 27 (3): 147–53. doi:10.1111/j.1365-2885.2004.00561.x. PMID 15189300.
  2. ^ "EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IBAFLIN" (PDF). European Medicines Agency. 1 September 2007.